Psychiatr. Pol. 2016; 50(2): 417–430
ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE)
www.psychiatriapolska.pl
DOI: http://dx.doi.org/10.12740/PP/OnlineFirst/59162

Lower urinary tract symptoms, nocturia and overactive bladder in patients with depression and anxiety

Tomasz Gołąbek[1], Michał Skalski[2], Mikołaj Przydacz[1], Agata Świerkosz[2], Marcin Siwek[3], Katarzyna Gołąbek[4], Klaudia Stangel-Wójcikiewicz[5], Dominika Dudek[3], Piotr L. Chłosta[1]

[1]Department of Urology, Jagiellonian University Medical College
[2]Department of Adult Psychiatry, University Hospital in Krakow
[3]Department of Affective Disorders, Jagiellonian University Medical College
[4]Sucha Beskidzka Regional Clinic, Sucha Beskidzka
[5]Department of Gynaecology and Oncology, University Hospital in Krakow

Summary

Lower urinary tract symptoms (LUTS) remain highly prevalent worldwide, and are well known to negatively impact patients' quality of life, sleep and psychosocial wellbeing. Conversely, both depression and anxiety have been shown to have a negative effect on perception, development and prolongation of LUTS. This paper provides an overview of an association between the lower urinary tract symptoms, depression and anxiety. It also explores possible common mechanisms underlying the causes of both conditions.

There has been a large body of evidence linking LUTS with anxiety and/or depression. Studies have documented not only a significant impact of LUTS on the psychosocial wellbeing, but also showed a strong negative effect of depression and anxiety on perception, development and prolongation of LUTS. High level of psychiatric morbidity has important implications on the appropriate management in patients with LUTS, as well as LUTS may have important implications on development and management of depression and anxiety. Therefore, clinicians should be aware of the bidirectional association between LUTS and anxiety and/or depression, as some patients may require a multidisciplinary approach and a combined treatment. The precise common mechanism underlying LUTS, depression and anxiety remain largely unknown and further research is needed to elucidate the underlying pathophysiological pathways.

Key words: lower urinary tract symptoms, depression, anxiety

Introduction

Lower urinary tract symptoms (LUTS) encompass storage (daytime urinary frequency, nocturia, urgency, urinary incontinence (UI)), voiding (hesitancy, straining, slow stream, intermittency, terminal dribble), and post-micturition symptoms (sensation of incomplete emptying, post-micturition dribble) [1]. LUTS are not disease or condition specific, and despite being commonly related to bladder outlet obstruction, LUTS may be indicative of bladder dysfunction and other structural and/or functional abnormalities of the urinary tract, as well as, they may herald many non-urological conditions [1, 2]. LUTS are particularly prevalent among adult men from the general population. In the Epidemiology Urinary Incontinence and Comorbidities (EPIC) study, which included a total of 19,165 adults from Canada, Germany, Italy, Sweden and the UK, an overall prevalence of LUTS was 62.5% in men and 66.6% in women aged ≥ 40 years [3]. In subgroup analysis 37.7% of all men reported having experienced only one LUTS subtype, whereas 24.8% reported having experienced more LUTS subtypes of which storage plus voiding LUTS (8.9% of the general population sample) were the most frequently reported LUTS cluster [4]. The Epidemiology of Lower Urinary Tract Symptoms (EpiLUTS) study, which was an internet-based population survey in Sweden, the USA and the UK, reported prevalence of at least one LUTS of at least "sometimes" frequency in 72.3%, and 76.3% of men and women, respectively [5]. Similarly, other studies have confirmed that LUTS are highly prevalent and costly condition worldwide [6].

Despite not being considered life threatening, numerous studies have demonstrated that LUTS exhibit a negative impact on health-related quality of life (HRQL), sleep, as well as on physical and mental health [5, 7–9].

Association of lower urinary tract symptoms with anxiety and depression

Anxiety and depression are a very common group of disease, with an overall prevalence of 2–16.5% [10–13]. Depression, which is expected to become the second leading cause of disease burden by 2020, plays an important role in the pathogenesis of numerous chronic conditions [14, 15]. A relationship between anxiety, depression and the LUTS has been the topic of many reports over the last few decades, with the first one describing this association in 1964 [16]. Several more recent and larger studies have investigated this link in a prospective manner. A large cohort study carried out on 1,980 Chinese men of 65 to 92 years of age, showed a significant association between moderate-to-severe LUTS and clinically relevant depressive disorders [17]. Importantly, a dose–response relationship was observed between mounting LUTS severity and increasing risk of clinically relevant depressive symptoms. Further corroborating data came from the Androx Vienna Municipality Study, which investigated LUTS and depression in a homogenous cohort of 673 healthy men, and found a significant association between these two symptom complexes [18]. Similarly, findings from the

EpiLUTS, a large observational longitudinal, multicentre study, which included 30,000 adult subjects, confirmed the negative effect of LUTS on the HRQL, and reported high level of anxiety and depression, with 35.9% of men and 53.3% of women meeting self-reported screening criteria for clinical anxiety (Hospital Anxiety and Depression Scale (HADS) score ≥ 8), and 29.8% of men and 37.6% of women meeting self-reported criteria for clinical depression (HADS ≥ 8) [7]. In a further sub-analysis of EpiLUTS, men with mixed urinary incontinence had the highest rates of clinically relevant anxiety (42.1%) compared to other types of UI [19]. However, in women, stress incontinence was predominantly associated with anxiety (49.7%), and depression (34.9%). Deleterious impact of LUTS on emotional wellbeing has also been shown in the EPIC study, a large, cross-sectional survey in Canada, Sweden, Germany, Italy, and the UK [20]. In nested control analysis presence of LUTS was significantly associated with depression compared to controls, with symptoms in three LUTS groups (overactive bladder syndrome (OAB), post-micturition and voiding symptoms) having the greatest impact on rate of depression. Further corroborating evidence of relationship between LUTS and anxiety and depression came from a recent study in Taiwan [21]. Data from a random population sample of enrolees in the National Health Insurance Programme in 2001–2009, consisted of 22,980 LUTS patients, and 45,960 matched controls. The results showed that patients with LUTS had a significantly higher prevalence of anxiety or depression than matched controls (11.5% versus 5.7%). After controlling for sociodemographic variables and other major systemic diseases, the odds ratios for anxiety, depression, either anxiety or depression, and both anxiety and depression, were 2.05; 2.19; 2.14 and 2.56, respectively.

Chances of depression causing LUTS were also subject to many investigations [20, 22–26]. The Boston Area Community Health (BACH) survey, a community-based epidemiologic survey, found that LUTS were significantly associated with depression, and that depression increased the odds of LUTS. Recently, an interesting report has been published. It examined the association of LUTS with suicidal ideation in 2,890 men from the National Health and Nutrition Examination Survey (NHANES), who were 40 years old or older [27]. Data from this cross-sectional study showed that men with more LUTS were more likely to have depression and suicidal ideation. Moreover, men with greater depression scores (the Patient Health Questionnaire-9 (PHQ-9) score ≥ 5, and ≥ 10 were used as a threshold for identifying the outcome of moderate and major depression, respectively) were more likely to suffer from LUTS. Based on the findings from the aforementioned studies a bidirectional nature of relationship between LUTS and the affective disorders should be considered.

The association between LUTS and anxiety and depression could be attributable to several different mechanisms. LUTS reduce HRQL, and can lead to embarrassment, social anxiety, demoralisation, and poor self-esteem [27]. Moreover, having LUTS may be perceived by the patients themselves, as well as their partners and family as a sign of weakness and aging [28]. Further, nocturia and disturbed sleep both result in daytime drowsiness, inability to concentrate and subsequent anxiety [29–31]. As a consequence

of this significant emotional distress related to LUTS, affective disorders may develop [32]. In addition, it has been suggested that stress accompanied by anxiety and/or depression may be an important factor contributing to the development and prolongation of LUTS [33]. Moreover, some antidepressants and anxiolytics have been suggested as the risk factors for LUTS [34]. Other possible mechanisms explaining coexistence of LUTS with depression and anxiety involve altered concentration of serotonin and norepinephrine in the central nervous system (CNS) in patients with LUTS, as well as, in those with anxiety and depression [35, 36]. Furthermore, increased adrenergic tone and the hypothalamic-pituitary axis have been proposed to mediate the depressive symptoms and LUTS. [37]. Finally, inflammation, which has been involved in the pathogenesis of both LUTS and depression, may also play a role [38, 39].

Nocturia, depression and anxiety

Nocturia is defined by the International Continence Society (ICS) as the complaint that individual has to wake at night one or more times to void; each void is preceded and followed by sleep [40]. It affects a large proportion of adults and is one of the most frequently reported lower urinary tract symptom [1, 3]. In the EPIC study, an overall prevalence of nocturia was 54.5% in women and 48.6% in men [3]. The prevalence increased with age in both sexes and ranged from 34.5% and 43.9% in younger (≤ 39yeras old) men and women, respectively, to 71.9% and 70.8% in older (≥ 60 years old) male and female individuals, respectively. Data from the National Sleep Foundation telephone pole conducted in a representative sample of 55–84 years old Americans obtained similar results with 53% of subjects reporting nocturia [41]. Notably, in this study nocturia was over four times as frequently as the next most often cited cause of poor sleep, the pain. More recent data from a cross-sectional telephone survey conducted in general population from five European countries on 22,740 non-institutionalised individuals aged 15 or over, also indicated that nocturia remains an important cause of insomnia [42].

Nocturia may be the symptom of some primary urological disorders including benign prostatic hyperplasia, benign prostatic enlargement or OAB, or may be related to heart disease, hormonal imbalances, sleep problems and lifestyle factors [1]. Regardless the cause, repeated fragmentation of sleep results in daytime drowsiness, poor concentration and anxiety which adversely affects occupational functioning, physical and emotional health, as well as, patient's quality of life [29–31]. Moreover, nocturia can also lead to embarrassment and poor self-esteem [43, 44]. In result, it may increase the risk of depression. This link was first described by Asplund et al. in 2004 [45]. In this study, conducted in an unselected group of 1,375 adults from Sweden, major depression was associated with a six-fold increase of nocturia in men, and a three-fold increase in women, after accounting for age and somatic health. In the BACH study, which investigated the association of nocturia with QoL and depressive symptoms in 5,203 men and women, the risk of depressive symptoms

in men with nocturia was 2.79 (95% confidence interval (CI): 1.81–4.31), whereas in women 1.80 (95% CI:1.29–2.51) [46]. Similarly, several other cross-sectional studies confirmed the association of nocturia with depression [30, 43, 45–51]. A recent systematic review on the relationship of depression and anxiety with nocturia, reported that waking up at night to void increased the odds of reporting depression from 1.2 to 20.24 [23].

Possibility of depression to cause nocturia was also subject to few investigations and the reported odds were from 1.2 to 7.73 [23, 43]. An elegantly designed prospective cohort Tampere Aging Male Urologic Study (TAMUS) from Finland assessed the effects of depressive symptoms on the incidence of nocturia in 1,580, 50–70-years old men followed for 5 years [44]. The results showed that the individuals with depressive symptoms at study entry were at 2.8 times higher risk (95% CI: 1.5–5.2) for moderate or severe nocturia than those without depressive symptoms. Of note, a dose-response relationship was found between the severity of depressive symptoms at baseline and the incidence of moderate or severe nocturia. However, nocturia at baseline had no significant effect on the odds of depressive symptoms during follow-up.

In TAMUS study, antidepressants or antipsychotic medications did not appear to increase the nocturia incidence rate (relative risk (95% CI), was 0.7 (0.4–1.4), and 1.1 (0.4–3.0) for mild, and moderate or severe nocturia, respectively). However, effects of selective serotonin reuptake inhibitors (SSRIs) on nocturia remain unclear. Although antidepressants have not been shown to affect day-to-night urine production ratio in some studies [44, 52], in a report by Asplund et al., SSRIs use doubled the risk of two or more nocturnal voids in both men and women [53].

An association of nocturia with anxiety has been investigated to much smaller extent than that with depression. The EpiLUTS study linked nocturia to clinically relevant anxiety (HADS score ≥ 8) in both men and women [7]. Similar results were published by another group [54].

The findings from aforementioned studies suggest that an association between nocturia and anxiety and depressive symptoms may be bidirectional in nature. However, as the level of evidence is 2 at its best (according to the Oxford Centre for Evidence-based Medicine classification), there is a need for further, well-designed studies that will clarify the exact nature of these associations [55].

Although the exact mechanisms that might explain a relationship between depression, anxiety and nocturia remain unknown, several shared pathophysiological pathways may need to be considered. Depressed patients have higher overall level of antidiuretic hormone (ADH) than healthy controls [56]. However, they lack normal rise in the ADH level. Consequently the loss of circadian rhythm of circulating ADH may contribute to nocturia [45]. Such abnormality is also a common mechanism of nocturnal polyuria in adult and elderly people [57, 58].

Another possible explanation may be a negative effect of sleep fragmentation and other causes of disturbed sleep on the nocturnal urine output. It has been shown that during sleep the urine output is lower than while awake [59, 60]. Of note, in depressed

patients insomnia is common [61]. Therefore, it seems possible that nocturia-related sleep disruption may lead to depression.

Further proposed mechanism linking affective disorders with nocturia involve altered concentration of serotonin and norepinephrine in the CNS [35, 36]. In rats, lowering serotonin levels in the CNS resulted in depression and overactive bladder [62, 63]. However, administration of serotonin reuptake inhibitors, as well as serotonin receptor agonists depressed reflex bladder contractions and increased the bladder volume threshold for inducing micturition [63].

Overactive bladder, depression and anxiety

Overactive bladder is defined by the International Continence Society as the presence of urinary urgency, usually accompanied by frequency (voiding 8 or more times in a 24-hour period) and nocturia (awakening at night to void), with or without urgency urinary incontinence, in the absence of UTI or other obvious pathology [40]. In general population, OAB prevalence rates range from 7% to 27% in men, and 9% to 43% in women, and tend to increase with age [3, 64, 65]. A number of population-based studies have reported the effect of OAB on HRQL [65]. Similarly, the relationship between OAB and affective disorders has been subject to many investigations [7, 66, 67].

Although a large body of evidence has supported a positive association of OAB and depression, a link between anxiety and OAB has been documented less extensively. A recent systematic review on affective symptoms and the overactive bladder, found that only six out of nine studies identified a positive relationship between OAB symptoms and anxiety, three showed no association, and two case-control studies reached contradictory conclusions [66].

The effect of OAB symptoms on anxiety and depression was observed in EpiLUTS study [7]. This cross-sectional population-representative survey was conducted on 30,000 participants from the USA, the UK and Sweden who rated their LUTS, condition-specific health related quality of life, generic health status, anxiety and depression (using HADS). In this study, OAB symptoms were markedly associated with positive HADS anxiety sub-scores. Data from the US EpiLUTS study not only has confirmed this observation, but it also identified patients with bothersome OAB symptoms to be the group more likely to report anxiety than that with OAB without bothersome symptoms [67]. Similar results provided the European part of the EpiLUTS study [68]. English and Swedish men and women with bothersome OAB were significantly more likely to seek treatment, report the lowest levels of HRQL and work productivity and the highest levels of anxiety and depression compared to those with no or minimal symptoms and OAB without bother. Moreover, greater severity of urgency, urgency urinary incontinence, frequency, nocturia, and increasing levels of anxiety were strongly predictive of OAB bother. These results may suggest a bidirectional relationship between overactive bladder and anxiety. However, more evidence is still required.

A relationship between depression and OAB has been much better documented than between anxiety and OAB. Based on cross-sectional cohort, as well as, randomised controlled studies it seems plausible that this association is bidirectional in nature. The National Overactive Bladder Evaluation (NOBLE) Programme, a telephone survey, was initiated to assess the prevalence and the impact of OAB in 5,204 English-speaking adults in the USA [24]. The results showed that OAB with and without urge incontinence was associated with higher the Centre for Epidemiologic Studies Depression Scale (CES-D) scores in both men and women than the OAB-negative controls. Additional sub-analysis limited to the 919 participants in the nested case-control study with 171 reporting urge, stress or mixed incontinence, confirmed presence of depressive symptoms (CES-D > 16) in all the incontinence groups. No significant differences regarding depression severity between incontinent subjects were found [3]. Another evidence supporting association of OAB symptoms with depression comes from the EPIC study [20, 25]. Of the EPIC participants, 1,434 identified cases of OAB were matched by age, gender and country with 1,434 controls. The nested case-controlled analysis revealed that depression with CES-D ≥ 21 was statistically more common in those with OAB (regardless of associated incontinence) than in controls (148 versus 46 individuals, respectively, $p < 0.001$) [25]. Further corroborating evidence of positive relationship between OAB symptoms and depression was provided by the participants from the EpiLUTS study. Those respondents to the survey questions who were bothered by OAB symptoms were more likely to report depression than individuals not reporting bother [19, 66, 68]. Interestingly, the respondents with OAB had a higher rate of anxiety (31%), and depressive symptoms (27%) compared to the rates from other cross-sectional reports [19, 24, 25, 69].

Many other investigators also linked depression with OAB [69–72]. However, the NOBLE, EPIC and EpiLUTS studies reported on the co-occurrence of OAB and depression, whereas a new onset of OAB in men and women with depression was reported in four studies [20, 24, 50, 73–75], and a new onset of depression in OAB patients was delineated by others [73, 74]. A bidirectional nature of this relationship seems therefore very likely.

Important data regarding OAB treatment-related modulation of the depressive symptoms comes from a randomised, multicentre controlled trial in a cohort of men with OAB by Staskin et al. [76]. In this study, all participants received oxybutynin patch for overactive bladder symptoms. The proportion of men with the Beck Depression Inventory-II (BDI-II) score > 12 (indicating depression) decreased from 23.9% to 17.9% after 6-month treatment period ($p = 0.0055$).

The association between OAB, depression and anxiety could be attributed to several mechanisms. Firstly, patients bothered by OAB symptoms have poor health-related quality of life [20, 76]. Secondly, OAB can have a considerable effect on daily activities and negatively affect self-esteem, which consequently may lead to anxiety and depression [20, 77]. In addition, OAB may also affect patients' mood indirectly by its negative impact on the quality of sleep [75, 78]. Moreover, it is possible that

stress associated with anxiety and/or depression may be a factor in the perception and development of OAB [33]. The association between OAB and anxiety or depression, may further be explained by the fact that these syndromes share common biological pathways. Some studies have shown that serotonin and norepinephrine are involved in the pathophysiology of anxiety and depression [35, 36]. In animal experiments, lowering serotonin levels in the CNS resulted in both hyperactivity of the bladder, and depressive symptoms [62, 63]. However, administration of SSRI, fluoxetine, reversed the urinary symptoms [79]. Similarly, in humans, administration of a serotonin and norepinephrine reuptake inhibitor (SNRI), duloxetine, led to significant improvements of symptoms in adult female patients with OAB compared with placebo group [80].

A neuro-endocrine explanation for association of OAB symptoms with depression and anxiety may be found in shared dysregulation of the hypothalamic–pituitary-adrenal axis, which plays a role in depression and anxiety disorders [81]. In addition, corticotrophin-releasing factor (CRF), a neuropeptide which acts within both the brain and the periphery to coordinate the overall response of the body to stress has been shown to have an inhibitory effect in the pontine-spinal pathway and lower micturition threshold and urine volume in an animal model [82, 83].

Another possible explanation linking OAB with depression and anxiety refers to the deleterious changes in the limbic system. The anterior cingulate cortex (ACC) is involved in autonomic emotional and motor arousal and in monitoring [84]. Moreover, the areas in the right anterior cingulate gyrus and the right inferior frontal gyrus are involved in voluntary voiding of healthy males [85]. It has been shown that dysfunction of the limbic system and hypoperfusion, especially in the anterior cingulate cortex, may be implicated in late-life depression in female patients [86]. In addition, genuine urge incontinence with reduced bladder filling sensation was associated with global hypoperfusion of the frontal areas of the brain in geriatric patients [85], and reduced anterior cingulate cortex activity accompanied by failure of inhibition of detrusor overactive contractions [87].

Conclusions

There has been a large body of evidence linking LUTS with anxiety and/or depression. Studies have documented not only a significant impact of LUTS on the psychosocial wellbeing, but also showed a strong negative effect of depression and anxiety on perception, development and prolongation of LUTS. High level of psychiatric morbidity has important implications on the appropriate management in patients with LUTS, as well as LUTS may have important implications on development and management of depression and anxiety. Therefore, clinicians should be aware of the bidirectional association between LUTS and anxiety and/or depression, as some patients may require a multidisciplinary approach and a combined treatment. The precise common mechanism underlying LUTS, depression and anxiety remain largely unknown and further research is needed to elucidate the underlying pathophysiological pathways.

References

1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C. et al. *EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction*. Eur. Urol. 2015; 67(6): 1099–1109.
2. Gołąbek T, Kiely E, O'Reilly B. *Detrusor overactivity in diabetic and non-diabetic patients: is there a difference?* Int. Braz. J. Urol. 2012; 38(5): 652–659.
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S. et al. *Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study*. Eur. Urol. 2006; 50(6): 1306–1314.
4. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. *Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder*. Eur. Urol. 2009; 56(1): 14–20.
5. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS. et al. *The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study*. BJU Int. 2009; 104(3): 352–360.
6. Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA, Members of the Florey Adelaide Male Ageing Study. *Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men*. World J. Urol. 2011; 29(2): 179–184.
7. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS. et al. *The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS*. BJU Int. 2009; 103(supl. 3): 4–11.
8. Fourcade RO, Lacoin F, Rouprêt M, Slama A, Le Fur C, Michel E. et al. *Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia*. World J. Urol. 2012; 30(3): 419–426.
9. Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. *Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years*. Eur. Urol. 2010; 58(1): 149–156.
10. Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P. et al. *Depressive disorders in Europe: prevalence figures from the ODIN study*. Br. J. Psychiatry 2001; 179: 308–316.
11. Rutter M, Maughan B. *Psychosocial adversities in childhood and adult psychopathology*. J. Pers. Disord. 1997; 11(1): 4–18.
12. Jarema M, Dudek D, Czernikiewicz A. *Cognitive dysfunctions in depression – underestimated symptomor new dimension?* Psychiatr. Pol. 2014; 48(6): 1105–1116.
13. Pietrzyk E, Gorczyca-Michta I, Michta K, Nowakowska M, Wożakowska-Kapłon B. *Depression in patients after coronary artery bypass grafting*. Psychiatr. Pol. 2014; 48(5): 987–996.
14. Michaud CM, Murray CJ, Bloom BR. *Burden of disease--implications for future research*. JAMA 2001; 285(5): 535–539.
15. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. *Depression, chronic diseases, and decrements in health: results from the World Health Surveys*. Lancet 2007; 370(9590): 851–858.
16. Engel WJ. *Uropsychiatry*. J. Mich. State Med. Soc. 1964; 63: 273–277.

17. Wong SY, Hong A, Leung J, Kwok T, Leung PC, Woo J. *Lower urinary tract symptoms and depressive symptoms in elderly men*. J. Affect. Disord. 2006; 96(1–2): 83–88.

18. Rom M, Schatzl G, Swietek N, Rücklinger E, Kratzik C. *Lower urinary tract symptoms and depression*. BJU Int. 2012; 110(11 Pt C): E918–E921.

19. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. *Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States*. Eur. Urol. 2012; 61(1): 88–95.

20. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. *The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study*. BJU Int. 2008; 101(11): 1388–1395.

21. Lung-Cheng Huang C, Ho CH, Weng SF, Hsu YW, Wang JJ, Wu MP. *The association of healthcare seeking behavior for anxiety and depression among patients with lower urinary tract symptoms: a nationwide population-based study*. Psychiatry Res. 2015; 226(1): 247–251.

22. Fitzgerald MP, Link CL, Litman HJ, Travison TG, McKinlay JB. *Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses*. Eur. Urol. 2007; 52(2): 407–415.

23. Breyer BN, Shindel AW, Erickson BA, Blaschko SD, Steers WD, Rosen RC. *The association of depression, anxiety and nocturia: a systematic review*. J. Urol. 2013; 190(3): 953–957.

24. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R. et al. *Prevalence and burden of overactive bladder in the United States*. World J. Urol. 2003; 20(6): 327–336.

25. Coyne KS, Zhou Z, Thompson C, Versi E. *The impact on health-related quality of life of stress, urge and mixed urinary incontinence*. BJU Int. 2003; 92(7): 731–735.

26. Koh JS, Ko HJ, Wang SM, Cho KJ, Kim JC, Lee SJ. et al. *The relationship between depression, anxiety, somatization, personality and symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia*. Psychiatry Investig. 2015; 12(2): 268–273.

27. Breyer BN, Kenfield SA, Blaschko SD, Erickson BA. *The association of lower urinary tract symptoms, depression and suicidal ideation: data from the 2005-2006 and 2007-2008 National Health and Nutrition Examination Survey*. J. Urol. 2014; 191(5): 1333–1339.

28. Wong SY, Woo J, Leung JC, Leung PC. *Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study*. Aging Male 2010; 13(2): 113–119.

29. Appell RA, Sand PK. *Nocturia: etiology, diagnosis, and treatment*. Neurourol. Urodyn. 2008; 27(1): 34–39.

30. Johnson TV, Abbasi A, Ehrlich SS, Kleris RS, Raison CL, Master VA. *Nocturia associated with depressive symptoms*. Urology 2011; 77(1): 183–186.

31. Ancoli-Israel S, Bliwise DL, Nørgaard JP. *The effect of nocturia on sleep*. Sleep Med. Rev. 2011; 15(2): 91–97.

32. Molinuevo B, Batista-Miranda JE. *Under the tip of the iceberg: psychological factors in incontinence*. Neurourol. Urodyn. 2012; 31(5): 669–671.

33. Cortes E, Sahai A, Pontari M, Kelleher C. *The psychology of LUTS: ICI-RS 2011*. Neurourol. Urodyn. 2012; 31(3): 340–343.

34. Wuerstle MC, Van Den Eeden SK, Poon KT, Quinn VP, Hollingsworth JM, Loo RK. et al. *Contribution of common medications to lower urinary tract symptoms in men*. Arch. Intern. Med. 2011; 171(18): 1680–1682.

35. Holmes A. *Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease*. Neurosci. Biobehav. Rev. 2008; 32(7): 1293–1314.

36. Hirayama A, Torimoto K, Mastusita C, Okamoto N, Morikawa M, Tanaka N. et al. *Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study*. Urology 2012; 80(1): 71–76.

37. Laumann EO, Kang JH, Glasser DB, Rosen RC, Carson CC. *Lower urinary tract symptoms are associated with depressive symptoms in white, black and Hispanic men in the United States*. J. Urol. 2008; 180(1): 233–240.

38. Johnson TV, Abbasi A, Ehrlich SS, Kleris RS, Chirumamilla SL, Schoenberg ED. et al. *Major depression drives severity of American Urological Association Symptom Index*. Urology 2010; 76(6): 1317–1320.

39. Miller AH, Maletic V, Raison CL. *Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression*. Biol. Psychiatry 2009; 65(9): 732–741.

40. van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S. et al. *The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society*. Neurourol. Urodyn. 2002; 21(2): 179–183.

41. Bliwise DL, Foley DJ, Vitiello MV, Ansari FP, Ancoli-Israel S, Walsh JK. *Nocturia and disturbed sleep in the elderly*. Sleep Med. 2009; 10(5): 540–548.

42. Ohayon MM. *Nocturnal awakenings and difficulty resuming sleep: their burden in the European general population*. J. Psychosom. Res. 2010; 69(6): 565–571.

43. Tikkinen KA, Auvinen A, Johnson TM 2nd, Weiss JP, Keränen T, Tiitinen A. et al. *A systematic evaluation of factors associated with nocturia--the population-based FINNO study*. Am. J. Epidemiol. 2009; 170(3): 361–368.

44. Häkkinen JT, Shiri R, Koskimäki J, Tammela TL, Auvinen A, Hakama M. *Depressive symptoms increase the incidence of nocturia: Tampere Aging Male Urologic Study (TAMUS)*. J. Urol. 2008; 179(5): 1897–1901.

45. Asplund R, Henriksson S, Johansson S, Isacsson G. *Nocturia and depression*. BJU Int. 2004; 93(9): 1253–1256.

46. Kupelian V, Wei JT, O'Leary MP, Norgaard JP, Rosen RC, McKinlay JB. *Nocturia and quality of life: results from the Boston area community health survey*. Eur. Urol. 2012; 61(1): 78–84.

47. Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP. et al. *Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health (BACH) Survey*. Urology 2009; 73(5): 950–957.

48. Gourova LW, van de Beek C, Spigt MG, Nieman FH, van Kerrebroeck PE. *Predictive factors for nocturia in elderly men: a cross-sectional study in 21 general practices*. BJU Int. 2006; 97(3): 528–532.

49. Markland AD, Vaughan CP, Johnson TM 2nd, Goode PS, Redden DT, Burgio KL. *Prevalence of nocturia in United States men: results from the National Health and Nutrition Examination Survey*. J. Urol. 2011; 185(3): 998–1002.

50. van der Vaart CH, Roovers JP, de Leeuw JR, Heintz AP. *Association between urogenital symptoms and depression in community-dwelling women aged 20 to 70 years*. Urology 2007; 69(4): 691–696.

51. Hsu A, Nakagawa S, Walter LC, Van Den Eeden SK, Brown JS, Thom DH. et al. *The burden of nocturia among middle-aged and older women*. Obstet. Gynecol. 2015; 125(1): 35–43.

52. Blanker MH, Bernsen RM, Ruud Bosch JL, Thomas S, Groeneveld FP, Prins A. et al. *Normal values and determinants of circadian urine production in older men: a population based study*. J. Urol. 2002; 168(4 Pt 1): 1453–1457.

53. Asplund R, Johansson S, Henriksson S, Isacsson G. *Nocturia, depression and antidepressant medication*. BJU Int. 2005; 95(6): 820–823.

54. H. Hashim, K. Coyne, C. Chapple, I. Milsom, Z. Kopp. *Nocturia: risk factors and associated comorbid conditions findings from an international cross-sectional study: EpiLUTS*. BJU Int. Suppl. 2009: 103: 4.

55. Centre for Evidence-Based Medicine. *Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)*. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ [retrieved: 06.07.2015].

56. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA. et al. *Plasma levels of arginine vasopressin elevated in patients with major depression*. Neuropsychopharmacology 1997; 17(4): 284–292.

57. Goessaert AS, Krott L, Hoebeke P, Vande Walle J, Everaert K. *Diagnosing the pathophysiologic mechanisms of nocturnal polyuria*. Eur. Urol. 2015; 67(2): 283–288.

58. Sands JM. *Urine concentrating and diluting ability during aging*. J. Gerontol. A Biol. Sci. Med. Sci. 2012; 67(12): 1352–1357.

59. Asplund R. *The nocturnal polyuria syndrome (NPS)*. Gen. Pharmacol. 1995; 26(6): 1203–1209.

60. Brandenberger G, Charloux A, Gronfier C, Otzenberger H. *Ultradian rhythms in hydromineral hormones*. Horm. Res. 1998; 49(3–4): 131–135.

61. Murphy MJ, Peterson MJ. *Sleep disturbances in depression*. Sleep Med. Clin. 2015; 10(1): 17–23.

62. Steers W. *Potential targets in the treatment of urinary incontinence*. Rev. Urol. 2001; 3(supl. 1): S19–S26.

63. de Groat WC. *Influence of central serotonergic mechanisms on lower urinary tract function*. Urology 2002; 59(5 supl. 1): 30–36.

64. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J. et al. *An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction*. Neurourol. Urodyn. 2010; 29(1): 4–20.

65. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. *National community prevalence of overactive bladder in the United States stratified by sex and age*. Urology 2011; 77(5): 1081–1087.

66. Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. *Affective symptoms and the overactive bladder – a systematic review*. J. Psychosom. Res. 2015; 78(2): 95–108.

67. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. *Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS*. Urology 2012; 80(1): 90–96.

68. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. *The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS*. BJU Int. 2011; 108(9): 1459–1471.

69. Ikeda Y, Nakagawa H, Ohmori-Matsuda K, Hozawa A, Masamune Y, Nishino Y. et al. *Risk factors for overactive bladder in the elderly population: a community-based study with face-to-face interview*. Int. J. Urol. 2011; 18(3): 212–218.

70. Melville JL, Walker E, Katon W, Lentz G, Miller J, Fenner D. *Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence*. Am. J. Obstet. Gynecol. 2002; 187(1): 80–87.

71. Sung VW, West DS, Hernandez AL, Wheeler TL 2nd, Myers DL, Subak LL. et al. *Association between urinary incontinence and depressive symptoms in overweight and obese women*. Am. J. Obstet. Gynecol. 2009; 200(5): 557.

72. Felde G, Bjelland I, Hunskaar S. *Anxiety and depression associated with incontinence in middle-aged women: a large Norwegian cross-sectional study*. Int. Urogynecol. J. 2012; 23(3): 299–306.

73. Perry S, McGrother CW, Turner K, Leicestershire MRC Incontinence Study Group. *An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model*. Br. J. Health Psychol. 2006; 11(3): 463–482.

74. van de Pol G, van Brummen HJ, Bruinse HW, Heintz AP, van der Vaart CH. *Is there an association between depressive and urinary symptoms during and after pregnancy*. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2007; 18(12): 1409–1415.

75. Nuotio M, Luukkaala T, Tammela TL, Jylhä M. *Six-year follow-up and predictors of urgency-associated urinary incontinence and bowel symptoms among the oldest old: a population-based study*. Arch. Gerontol. Geriatr. 2009; 49(2): e85–e90.

76. Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. *Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions*. Int. J. Clin. Pract. 2008; 62(1): 27–38.

77. Nicolson P, Kopp Z, Chapple CR, Kelleher C. *It's just the worry about not being able to control it! A qualitative study of living with overactive bladder*. Br. J. Health Psychol. 2008; 13(2): 343–359.

78. Krystal AD, Preud'homme XA, Amundsen CL, Webster GD. *Detrusor overactivity persisting at night and preceding nocturia in patients with overactive bladder syndrome: a nocturnal cystometrogram and polysomnogram study*. J. Urol. 2010; 184(2): 623–628.

79. Lee KS, Na YG, Dean-McKinney T, Klausner AP, Tuttle JB, Steers WD. *Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine*. J. Urol. 2003; 170(5): 2067–2071.

80. Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I. et al. *Duloxetine compared with placebo for treating women with symptoms of overactive bladder*. BJU Int. 2007; 100(2): 337–345.

81. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. *The role of corticotropin-releasing factor in depression and anxiety disorders*. J. Endocrinol. 1999; 160(1): 1–12.

82. Klausner AP, Steers WD. *Corticotropin releasing factor: a mediator of emotional influences on bladder function*. J. Urol. 2004; 172(6 Pt 2): 2570–2573.

83. Klausner AP1, Streng T, Na YG, Raju J, Batts TW, Tuttle JB. et al. *The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat*. Auton. Neurosci. 2005; 123(1–2): 26–35.

84. Botvinick MM, Cohen JD, Carter CS. *Conflict monitoring and anterior cingulate cortex: an update*. Trends Cogn. Sci. 2004; 8(12): 539–546.

85. Awata S, Ito H, Konno M, Ono S, Kawashima R, Fukuda H. et al. *Regional cerebral blood flow abnormalities in late-life depression: relation to refractoriness and chronification*. Psychiatry Clin. Neurosci. 1998; 52(1): 97–105.

86. Griffiths D. *Clinical studies of cerebral and urinary tract function in elderly people with urinary incontinence*. Behav. Brain Res. 1998; 92(2): 151–155.

87. Blok BF, Willemsen AT, Holstege G. *A PET study on brain control of micturition in humans*. Brain 1997; 120(1): 111–121.

Address: Tomasz Gołąbek
Chair and Department of Urology
Jagiellonian University Medical College
31-531 Kraków, Grzegórzecka Street 18